MAPT and Alzheimer disease: By contrast, a p-tau assay that uses the same phosphorylation-specific antibody for both capture and detection (IMR method) thus exclusively targeting phosphorylation at threonine-181 irrespective of the fragment(s) on which this occurs [126] is increased not only in AD but also in other neurogenerative disorders [89].